ILMN250502C89000
- 0.25
- 0.000.00%
Illumina Newsroom
Should You Hold Illumina (ILMN)?
This Cancer Test Could Become Routine -- and a Big Seller, Says Analyst -- Barrons.com
Leerink Partners Maintains Illumina(ILMN.US) With Buy Rating, Announces Target Price $115
Bernstein Maintains Illumina(ILMN.US) With Hold Rating, Cuts Target Price to $90
Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations
Express News | Illumina Inc : Bernstein Cuts Target Price to $90 From $130
Illumina and Tempus Partner to Drive the Future of Precision Medicine Through Genomic AI Innovation
Bank of America lowers the Target Price for Illumina to $75.
Bank of America: Downgraded Illumina's Target Price from $90 to $75, maintaining a "underperforming Large Cap" rating. (Gelonghui)
Piper Sandler Maintains Illumina(ILMN.US) With Buy Rating, Maintains Target Price $190
Life Sciences Companies Likely to See Surprisingly Good 1Q Results -- Market Talk
BofA Securities Cuts Price Target on Illumina to $75 From $90, Keeps Underperform Rating
Barclays lowered the Target Price of Illumina to $77.
Barclays: Downgraded Illumina's Target Price from $100 to $77, maintaining a Shareholding rating. (Gelonghui)
Bernstein Maintains Illumina(ILMN.US) With Hold Rating, Maintains Target Price $130
Illumina Is Maintained at Underweight by Barclays
Express News | Illumina : Barclays Cuts Target Price to $77 From $100
TD Cowen Maintains Illumina(ILMN.US) With Hold Rating, Cuts Target Price to $86
Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025
RBC Capital Maintains Illumina(ILMN.US) With Buy Rating, Cuts Target Price to $112
Illumina Is Maintained at Outperform by RBC Capital
RBC Cuts Price Target on Illumina to $112 From $128, Keeps Outperform Rating